A 2025 analysis published in The Lancet noted that most of the underlying data came from randomized controlled trials lasting about eight weeks and that prominent side effects such as sexual dysfunction, gastrointestinal issues, and emotional blunting were not evaluated in the analysis.
October 23, 2025
high
temporal
Key methodological limitation and omitted outcome domains in the analysis.
Medical interventions for pediatric gender dysphoria have been associated in the literature with potential risks including infertility or sterility, sexual dysfunction, impaired bone-density accrual, adverse cognitive impacts, cardiovascular disease and metabolic disorders, psychiatric disorders, surgical complications, and regret.
high
descriptive
Reviews of the medical literature commonly list these risks when evaluating benefits and harms of pediatric gender-affirming interventions.